nach oben

Current Cardiology Reports

Erschienen in:

01.08.2021 | Hypertension (DS Geller and DL Cohen, Section Editors)

Primary Aldosteronism: a Continuum from Normotension to Hypertension

verfasst von: Taweesak Wannachalee, Adina F. Turcu

Erschienen in: Current Cardiology Reports | Ausgabe 8/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Primary aldosteronism (PA) is the most common cause of secondary hypertension. Emerging evidence suggests that PA is associated with cardiovascular, metabolic, and renal complications, that likely develop insidiously, due to prolonged inappropriate mineralocorticoid receptor activation. In this review, we discuss the expanding clinical and pathological spectrum of PA.

Recent Findings

Clinical and molecular studies conducted over the recent years reveal that PA traverses a series of contiguous stages. Pre-clinical, but hormonally overt PA has been identified in patients with normal blood pressure, and such patients harbor an increased risk of developing hypertension. Similarly, genetic and histopathological advancements have exposed a spectrum of PA pathology that corresponds to a continuum that spans from pre-clinical stages to florid PA.

Summary

PA evolves from pre-hypertensive stages to resistant hypertension, along with serious cardiovascular and renal consequences. Early recognition of PA and targeted therapy will be essential for cardiovascular morbidity and mortality prevention in a large number of patients.

Conn JW. Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med. 1955;45(1):3–17.PubMed

Conn JW. Aldosterone in clinical medicine; past, present, and future. AMA Arch Intern Med. 1956;97(2):135–44. https://doi.org/10.1001/archinte.1956.00250200011001.CrossRefPubMed

Fishman LM, Kuchel O, Liddle GW, Michelakis AM, Gordon RD, Chick WT. Incidence of primary aldosteronism uncomplicated “essential” hypertension. A prospective study with elevated aldosterone secretion and suppressed plasma renin activity used as diagnostic criteria. JAMA. 1968;205(7):497–502. https://doi.org/10.1001/jama.205.7.497.CrossRefPubMed

Kaplan NM. Hypokalemia in the hypertensive patient, with observations on the incidence of primary aldosteronism. Ann Intern Med. 1967;66(6):1079–90. https://doi.org/10.7326/0003-4819-66-6-1079.CrossRefPubMed

• Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(5):1889–916. https://doi.org/10.1210/jc.2015-4061These are the current Endocrine Society guidelines for PA screening, diagnosis, and treatment.CrossRefPubMed

Hannemann A, Wallaschofski H. Prevalence of primary aldosteronism in patient's cohorts and in population-based studies--a review of the current literature. Horm Metab Res. 2012;44(3):157–62. https://doi.org/10.1055/s-0031-1295438.CrossRefPubMed

Monticone S, Burrello J, Tizzani D, Bertello C, Viola A, Buffolo F, et al. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J Am Coll Cardiol. 2017;69(14):1811–20. https://doi.org/10.1016/j.jacc.2017.01.052.CrossRefPubMed

Yang Y, Reincke M, Williams TA. Prevalence, diagnosis and outcomes of treatment for primary aldosteronism. Best Pract Res Clin Endocrinol Metab. 2020;34(2):101365. https://doi.org/10.1016/j.beem.2019.101365.CrossRefPubMed

Kayser SC, Dekkers T, Groenewoud HJ, van der Wilt GJ, Carel Bakx J, van der Wel MC, et al. Study heterogeneity and estimation of prevalence of primary aldosteronism: a systematic review and meta-regression analysis. J Clin Endocrinol Metab. 2016;101(7):2826–35. https://doi.org/10.1210/jc.2016-1472.CrossRefPubMed

10.

Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol. 2006;48(11):2293–300. https://doi.org/10.1016/j.jacc.2006.07.059.CrossRefPubMed

11.

Mosso L, Carvajal C, Gonzalez A, Barraza A, Avila F, Montero J, et al. Primary aldosteronism and hypertensive disease. Hypertension. 2003;42(2):161–5. https://doi.org/10.1161/01.HYP.0000079505.25750.11.CrossRefPubMed

12.

Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension. 2002;40(6):892–6. https://doi.org/10.1161/01.hyp.0000040261.30455.b6.CrossRefPubMed

13.

Douma S, Petidis K, Doumas M, Papaefthimiou P, Triantafyllou A, Kartali N, et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet. 2008;371(9628):1921–6. https://doi.org/10.1016/S0140-6736(08)60834-X.CrossRefPubMed

14.

Burrello J, Monticone S, Losano I, Cavaglia G, Buffolo F, Tetti M, et al. Prevalence of Hypokalemia and primary aldosteronism in 5100 patients referred to a tertiary hypertension unit. Hypertension. 2020;75(4):1025–33. https://doi.org/10.1161/HYPERTENSIONAHA.119.14063.CrossRefPubMed

15.

Jaffe G, Gray Z, Krishnan G, Stedman M, Zheng Y, Han J, et al. Screening rates for primary aldosteronism in resistant hypertension: a cohort study. Hypertension. 2020;75(3):650–9. https://doi.org/10.1161/HYPERTENSIONAHA.119.14359.CrossRefPubMed

16.

Ruhle BC, White MG, Alsafran S, Kaplan EL, Angelos P, Grogan RH. Keeping primary aldosteronism in mind: deficiencies in screening at-risk hypertensives. Surgery. 2019;165(1):221–7. https://doi.org/10.1016/j.surg.2018.05.085.CrossRefPubMed

17.

Mulatero P, Monticone S, Burrello J, Veglio F, Williams TA, Funder J. Guidelines for primary aldosteronism: uptake by primary care physicians in Europe. J Hypertens. 2016;34(11):2253–7. https://doi.org/10.1097/HJH.0000000000001088.CrossRefPubMed

18.

Vaidya A, Mulatero P, Baudrand R, Adler GK. The expanding spectrum of primary aldosteronism: implications for diagnosis, pathogenesis, and treatment. Endocr Rev. 2018;39(6):1057–88. https://doi.org/10.1210/er.2018-00139.CrossRefPubMedPubMedCentral

19.

Byrd JB, Turcu AF, Auchus RJ. Primary aldosteronism: practical approach to diagnosis and management. Circulation. 2018;138(8):823–35. https://doi.org/10.1161/CIRCULATIONAHA.118.033597.CrossRefPubMedPubMedCentral

20.

Vaidya A, Carey RM. Evolution of the primary aldosteronism syndrome: updating the approach. J Clin Endocrinol Metab. 2020;105(12). https://doi.org/10.1210/clinem/dgaa606.

21.

Lefebvre H, Prevost G, Louiset E. Autocrine/paracrine regulatory mechanisms in adrenocortical neoplasms responsible for primary adrenal hypercorticism. Eur J Endocrinol. 2013;169(5):R115–38. https://doi.org/10.1530/EJE-13-0308.CrossRefPubMed

22.

Perraudin V, Delarue C, Lefebvre H, Do Rego JL, Vaudry H, Kuhn JM. Evidence for a role of vasopressin in the control of aldosterone secretion in primary aldosteronism: in vitro and in vivo studies. J Clin Endocrinol Metab. 2006;91(4):1566–72. https://doi.org/10.1210/jc.2005-1453.CrossRefPubMed

23.

St-Jean M, Ghorayeb NE, Bourdeau I, Lacroix A. Aberrant G-protein coupled hormone receptor in adrenal diseases. Best Pract Res Clin Endocrinol Metab. 2018;32(2):165–87. https://doi.org/10.1016/j.beem.2018.01.003.CrossRefPubMed

24.

Ye P, Mariniello B, Mantero F, Shibata H, Rainey WE. G-protein-coupled receptors in aldosterone-producing adenomas: a potential cause of hyperaldosteronism. J Endocrinol. 2007;195(1):39–48. https://doi.org/10.1677/JOE-07-0037.CrossRefPubMed

25.

Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. Lancet Diabetes Endocrinol. 2018;6(1):51–9. https://doi.org/10.1016/S2213-8587(17)30367-4.CrossRefPubMed

26.

Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A. Incidence of atrial fibrillation and mineralocorticoid receptor activity in patients with medically and surgically treated primary aldosteronism. JAMA Cardiol. 2018;3(8):768–74. https://doi.org/10.1001/jamacardio.2018.2003.CrossRefPubMedPubMedCentral

27.

Mulatero P, Monticone S, Bertello C, Viola A, Tizzani D, Iannaccone A, et al. Long-term cardio- and cerebrovascular events in patients with primary aldosteronism. J Clin Endocrinol Metab. 2013;98(12):4826–33. https://doi.org/10.1210/jc.2013-2805.CrossRefPubMed

28.

Fallo F, Veglio F, Bertello C, Sonino N, Della Mea P, Ermani M, et al. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab. 2006;91(2):454–9. https://doi.org/10.1210/jc.2005-1733.CrossRefPubMed

29.

Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A. Renal outcomes in medically and surgically treated primary aldosteronism. Hypertension. 2018;72(3):658–66. https://doi.org/10.1161/HYPERTENSIONAHA.118.11568.CrossRefPubMed

30.

Reincke M, Fischer E, Gerum S, Merkle K, Schulz S, Pallauf A, et al. Observational study mortality in treated primary aldosteronism: the German Conn’s registry. Hypertension. 2012;60(3):618–24. https://doi.org/10.1161/HYPERTENSIONAHA.112.197111.CrossRefPubMed

31.

Rossi GP. Primary aldosteronism: JACC state-of-the-art review. J Am Coll Cardiol. 2019;74(22):2799–811. https://doi.org/10.1016/j.jacc.2019.09.057.CrossRefPubMed

32.

Stowasser M, Gordon RD. Primary aldosteronism: changing definitions and new concepts of physiology and pathophysiology both inside and outside the kidney. Physiol Rev. 2016;96(4):1327–84. https://doi.org/10.1152/physrev.00026.2015.CrossRefPubMed

33.

Wu VC, Wang SM, Chang CH, Hu YH, Lin LY, Lin YH, et al. Long term outcome of aldosteronism after target treatments. Sci Rep. 2016;6:32103. https://doi.org/10.1038/srep32103.CrossRefPubMedPubMedCentral

34.

Rizzoni D, Porteri E, Castellano M, Bettoni G, Muiesan ML, Tiberio G, et al. Endothelial dysfunction in hypertension is independent from the etiology and from vascular structure. Hypertension. 1998;31(1 Pt 2):335–41. https://doi.org/10.1161/01.hyp.31.1.335.CrossRefPubMed

35.

Stowasser M, Sharman J, Leano R, Gordon RD, Ward G, Cowley D, et al. Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I. J Clin Endocrinol Metab. 2005;90(9):5070–6. https://doi.org/10.1210/jc.2005-0681.CrossRefPubMed

36.

Freel EM, Mark PB, Weir RA, McQuarrie EP, Allan K, Dargie HJ, et al. Demonstration of blood pressure-independent noninfarct myocardial fibrosis in primary aldosteronism: a cardiac magnetic resonance imaging study. Circ Cardiovasc Imaging. 2012;5(6):740–7. https://doi.org/10.1161/CIRCIMAGING.112.974576.CrossRefPubMed

37.

Monticone S, D'Ascenzo F, Moretti C, Williams TA, Veglio F, Gaita F, et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2018;6(1):41–50. https://doi.org/10.1016/S2213-8587(17)30319-4.CrossRefPubMed

38.

Rossi GP, Cesari M, Cuspidi C, Maiolino G, Cicala MV, Bisogni V, et al. Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism. Hypertension. 2013;62(1):62–9. https://doi.org/10.1161/HYPERTENSIONAHA.113.01316.CrossRefPubMed

39.

Iwakura Y, Morimoto R, Kudo M, Ono Y, Takase K, Seiji K, et al. Predictors of decreasing glomerular filtration rate and prevalence of chronic kidney disease after treatment of primary aldosteronism: renal outcome of 213 cases. J Clin Endocrinol Metab. 2014;99(5):1593–8. https://doi.org/10.1210/jc.2013-2180.CrossRefPubMed

40.

Piaditis G, Markou A, Papanastasiou L, Androulakis II, Kaltsas G. Progress in aldosteronism: a review of the prevalence of primary aldosteronism in pre-hypertension and hypertension. Eur J Endocrinol. 2015;172(5):R191–203. https://doi.org/10.1530/EJE-14-0537.CrossRefPubMed

41.

Rossi E, Regolisti G, Negro A, Sani C, Davoli S, Perazzoli F. High prevalence of primary aldosteronism using postcaptopril plasma aldosterone to renin ratio as a screening test among Italian hypertensives. Am J Hypertens. 2002;15(10 Pt 1):896–902. https://doi.org/10.1016/s0895-7061(02)02969-2.CrossRefPubMed

42.

Calhoun DA, Nishizaka MK, Zaman MA, Harding SM. Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea. Chest. 2004;125(1):112–7. https://doi.org/10.1378/chest.125.1.112.CrossRefPubMed

43.

Goodfriend TL, Calhoun DA. Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy. Hypertension. 2004;43(3):518–24. https://doi.org/10.1161/01.HYP.0000116223.97436.e5.CrossRefPubMed

44.

Hu Y, Zhang J, Liu W, Su X. Determining the prevalence of primary aldosteronism in patients with new-onset type 2 diabetes and hypertension. J Clin Endocrinol Metab. 2020;105(4). https://doi.org/10.1210/clinem/dgz293.

45.

Strauch B, Zelinka T, Hampf M, Bernhardt R, Widimsky J Jr. Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Hum Hypertens. 2003;17(5):349–52. https://doi.org/10.1038/sj.jhh.1001554.CrossRefPubMed

46.

Williams JS, Williams GH, Raji A, Jeunemaitre X, Brown NJ, Hopkins PN, et al. Prevalence of primary hyperaldosteronism in mild to moderate hypertension without hypokalaemia. J Hum Hypertens. 2006;20(2):129–36. https://doi.org/10.1038/sj.jhh.1001948.CrossRefPubMed

47.

Xu Z, Yang J, Hu J, Song Y, He W, Luo T, et al. Primary aldosteronism in patients in China with recently detected hypertension. J Am Coll Cardiol. 2020;75(16):1913–22. https://doi.org/10.1016/j.jacc.2020.02.052.CrossRefPubMed

48.

Montori VM, Young WF Jr. Use of plasma aldosterone concentration-to-plasma renin activity ratio as a screening test for primary aldosteronism. A systematic review of the literature. Endocrinol Metab Clin N Am. 2002;31(3):619–32, xi. https://doi.org/10.1016/s0889-8529(02)00013-0.CrossRef

49.

Yozamp N, Hundemer GL, Moussa M, Underhill J, Fudim T, Sacks B, et al. Intraindividual variability of aldosterone concentrations in primary aldosteronism: implications for case detection. Hypertension. 2020:HYPERTENSIONAHA12016429. https://doi.org/10.1161/HYPERTENSIONAHA.120.16429.

50.

Tanabe A, Naruse M, Takagi S, Tsuchiya K, Imaki T, Takano K. Variability in the renin/aldosterone profile under random and standardized sampling conditions in primary aldosteronism. J Clin Endocrinol Metab. 2003;88(6):2489–94. https://doi.org/10.1210/jc.2002-021476.CrossRefPubMed

51.

Tu W, Eckert GJ, Hannon TS, Liu H, Pratt LM, Wagner MA, et al. Racial differences in sensitivity of blood pressure to aldosterone. Hypertension. 2014;63(6):1212–8. https://doi.org/10.1161/HYPERTENSIONAHA.113.02989.CrossRefPubMed

52.

Kline GA, Darras P, Leung AA, So B, Chin A, Holmes DT. Surprisingly low aldosterone levels in peripheral veins following intravenous sedation during adrenal vein sampling: implications for the concept of nonsuppressibility in primary aldosteronism. J Hypertens. 2019;37(3):596–602. https://doi.org/10.1097/HJH.0000000000001905.CrossRefPubMed

53.

Siragy HM, Vieweg WV, Pincus S, Veldhuis JD. Increased disorderliness and amplified basal and pulsatile aldosterone secretion in patients with primary aldosteronism. J Clin Endocrinol Metab. 1995;80(1):28–33. https://doi.org/10.1210/jcem.80.1.7829626.CrossRefPubMed

54.

Barigou M, Ah-Kang F, Orloff E, Amar J, Chamontin B, Bouhanick B. Effect of postural changes on aldosterone to plasma renin ratio in patients with suspected secondary hypertension. Ann Cardiol Angeiol (Paris). 2015;64(3):169–74. https://doi.org/10.1016/j.ancard.2015.04.017.CrossRef

55.

Giacchetti G, Ronconi V, Lucarelli G, Boscaro M, Mantero F. Analysis of screening and confirmatory tests in the diagnosis of primary aldosteronism: need for a standardized protocol. J Hypertens. 2006;24(4):737–45. https://doi.org/10.1097/01.hjh.0000217857.20241.0f.CrossRefPubMed

56.

Pilz S, Kienreich K, Gaksch M, Grubler M, Verheyen N, Bersuch LA, et al. Aldosterone to active renin ratio as screening test for primary aldosteronism: reproducibility and influence of orthostasis and salt loading. Horm Metab Res. 2014;46(6):427–32. https://doi.org/10.1055/s-0034-1367033.CrossRefPubMed

57.

Baudrand R, Guarda FJ, Torrey J, Williams G, Vaidya A. Dietary sodium restriction increases the risk of misinterpreting mild cases of primary aldosteronism. J Clin Endocrinol Metab. 2016;101(11):3989–96. https://doi.org/10.1210/jc.2016-1963.CrossRefPubMedPubMedCentral

58.

Schwartz GL, Turner ST. Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. Clin Chem. 2005;51(2):386–94. https://doi.org/10.1373/clinchem.2004.041780.CrossRefPubMed

59.

Tezuka Y, Turcu AF. Mineralocorticoid receptor antagonists decrease the rates of positive screening for primary aldosteronism. Endocr Pract. 2020;26:1416–24. https://doi.org/10.4158/EP-2020-0277.CrossRefPubMed

60.

Brown MJ, Hopper RV. Calcium-channel blockade can mask the diagnosis of Conn's syndrome. Postgrad Med J. 1999;75(882):235–6. https://doi.org/10.1136/pgmj.75.882.235.CrossRefPubMedPubMedCentral

61.

Gradman AH, Kad R. Renin inhibition in hypertension. J Am Coll Cardiol. 2008;51(5):519–28. https://doi.org/10.1016/j.jacc.2007.10.027.CrossRefPubMed

62.

Mulatero P, Rabbia F, Milan A, Paglieri C, Morello F, Chiandussi L, et al. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension. 2002;40(6):897–902. https://doi.org/10.1161/01.hyp.0000038478.59760.41.CrossRefPubMed

63.

Stowasser M, Gordon RD, Rutherford JC, Nikwan NZ, Daunt N, Slater GJ. Diagnosis and management of primary aldosteronism. J Renin-Angiotensin-Aldosterone Syst. 2001;2(3):156–69. https://doi.org/10.3317/jraas.2001.022.CrossRefPubMed

64.

Stowasser M, Ahmed AH, Pimenta E, Taylor PJ, Gordon RD. Factors affecting the aldosterone/renin ratio. Horm Metab Res. 2012;44(3):170–6. https://doi.org/10.1055/s-0031-1295460.CrossRefPubMed

65.

Loh KC, Koay ES, Khaw MC, Emmanuel SC, Young WF Jr. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab. 2000;85(8):2854–9. https://doi.org/10.1210/jcem.85.8.6752.CrossRefPubMed

66.

Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L, et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab. 2004;89(3):1045–50. https://doi.org/10.1210/jc.2003-031337.CrossRefPubMed

67.

Tiu SC, Choi CH, Shek CC, Ng YW, Chan FK, Ng CM, et al. The use of aldosterone-renin ratio as a diagnostic test for primary hyperaldosteronism and its test characteristics under different conditions of blood sampling. J Clin Endocrinol Metab. 2005;90(1):72–8. https://doi.org/10.1210/jc.2004-1149.CrossRefPubMed

68.

•• Brown JM, Siddiqui M, Calhoun DA, Carey RM, Hopkins PN, Williams GH, et al. The Unrecognized prevalence of primary aldosteronism: a cross-sectional study. Ann Intern Med. 2020;173(1):10–20. https://doi.org/10.7326/M20-0065This recent cohort study revealed that PA prevalence increases gradually across the spectrum of blood pressure, from normotension to resistant hypertension.CrossRefPubMedPubMedCentral

69.

Tsiavos V, Markou A, Papanastasiou L, Kounadi T, Androulakis II, Voulgaris N, et al. A new highly sensitive and specific overnight combined screening and diagnostic test for primary aldosteronism. Eur J Endocrinol. 2016;175(1):21–8. https://doi.org/10.1530/EJE-16-0003.CrossRefPubMed

70.

Parasiliti-Caprino M, Lopez C, Prencipe N, Lucatello B, Settanni F, Giraudo G, et al. Prevalence of primary aldosteronism and association with cardiovascular complications in patients with resistant and refractory hypertension. J Hypertens. 2020;38(9):1841–8. https://doi.org/10.1097/HJH.0000000000002441.CrossRefPubMed

71.

Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159–219. https://doi.org/10.1093/eurheartj/eht151.CrossRefPubMed

72.

Brown JM, Robinson-Cohen C, Luque-Fernandez MA, Allison MA, Baudrand R, Ix JH, et al. The spectrum of subclinical primary aldosteronism and incident hypertension: a cohort study. Ann Intern Med. 2017;167(9):630–41. https://doi.org/10.7326/M17-0882.CrossRefPubMedPubMedCentral

73.

Baudrand R, Guarda FJ, Fardella C, Hundemer G, Brown J, Williams G, et al. Continuum of renin-independent aldosteronism in normotension. Hypertension. 2017;69(5):950–6. https://doi.org/10.1161/HYPERTENSIONAHA.116.08952.CrossRefPubMed

74.

Adlin EV. Subclinical primary aldosteronism. Ann Intern Med. 2017;167(9):673–4. https://doi.org/10.7326/M17-2237.CrossRefPubMed

75.

Markou A, Pappa T, Kaltsas G, Gouli A, Mitsakis K, Tsounas P, et al. Evidence of primary aldosteronism in a predominantly female cohort of normotensive individuals: a very high odds ratio for progression into arterial hypertension. J Clin Endocrinol Metab. 2013;98(4):1409–16. https://doi.org/10.1210/jc.2012-3353.CrossRefPubMed

76.

Newton-Cheh C, Guo CY, Gona P, Larson MG, Benjamin EJ, Wang TJ, et al. Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample. Hypertension. 2007;49(4):846–56. https://doi.org/10.1161/01.HYP.0000258554.87444.91.CrossRefPubMed

77.

Vasan RS, Evans JC, Larson MG, Wilson PW, Meigs JB, Rifai N, et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med. 2004;351(1):33–41. https://doi.org/10.1056/NEJMoa033263.CrossRefPubMed

78.

Seidel E, Schewe J, Scholl UI. Genetic causes of primary aldosteronism. Exp Mol Med. 2019;51(11):1–12. https://doi.org/10.1038/s12276-019-0337-9.CrossRefPubMed

79.

Fernandes-Rosa FL, Boulkroun S, Zennaro MC. Genetic and genomic mechanisms of primary aldosteronism. Trends Mol Med. 2020;26(9):819–32. https://doi.org/10.1016/j.molmed.2020.05.005.CrossRefPubMed

80.

Nanba K, Omata K, Else T, Beck PCC, Nanba AT, Turcu AF, et al. Targeted molecular characterization of aldosterone-producing adenomas in white Americans. J Clin Endocrinol Metab. 2018;103(10):3869–76. https://doi.org/10.1210/jc.2018-01004.CrossRefPubMedPubMedCentral

81.

Nanba K, Omata K, Gomez-Sanchez CE, Stratakis CA, Demidowich AP, Suzuki M, et al. Genetic characteristics of aldosterone-producing adenomas in blacks. Hypertension. 2019;73(4):885–92. https://doi.org/10.1161/HYPERTENSIONAHA.118.12070.CrossRefPubMed

82.

De Sousa K, Boulkroun S, Baron S, Nanba K, Wack M, Rainey WE, et al. Genetic, cellular, and molecular heterogeneity in adrenals with aldosterone-producing adenoma. Hypertension. 2020;75(4):1034–44. https://doi.org/10.1161/HYPERTENSIONAHA.119.14177.CrossRefPubMed

83.

Dutta RK, Arnesen T, Heie A, Walz M, Alesina P, Soderkvist P, et al. A somatic mutation in CLCN2 identified in a sporadic aldosterone-producing adenoma. Eur J Endocrinol. 2019;181(5):K37–41. https://doi.org/10.1530/EJE-19-0377.CrossRefPubMed

84.

Nanba K, Blinder AR, Rege J, Hattangady NG, Else T, Liu CJ, et al. Somatic CACNA1H mutation as a cause of aldosterone-producing adenoma. Hypertension. 2020;75(3):645–9. https://doi.org/10.1161/HYPERTENSIONAHA.119.14349.CrossRefPubMed

85.

Nishimoto K, Tomlins SA, Kuick R, Cani AK, Giordano TJ, Hovelson DH, et al. Aldosterone-stimulating somatic gene mutations are common in normal adrenal glands. Proc Natl Acad Sci U S A. 2015;112(33):E4591–9. https://doi.org/10.1073/pnas.1505529112.CrossRefPubMedPubMedCentral

86.

Omata K, Satoh F, Morimoto R, Ito S, Yamazaki Y, Nakamura Y, et al. Cellular and genetic causes of idiopathic hyperaldosteronism. Hypertension. 2018;72(4):874–80. https://doi.org/10.1161/HYPERTENSIONAHA.118.11086.CrossRefPubMed

87.

Nanba K, Vaidya A, Williams GH, Zheng I, Else T, Rainey WE. Age-related autonomous aldosteronism. Circulation. 2017;136(4):347–55. https://doi.org/10.1161/CIRCULATIONAHA.117.028201.CrossRefPubMedPubMedCentral

88.

Omata K, Anand SK, Hovelson DH, Liu CJ, Yamazaki Y, Nakamura Y, et al. Aldosterone-producing cell clusters frequently harbor somatic mutations and accumulate with age in normal adrenals. J Endocr Soc. 2017;1(7):787–99. https://doi.org/10.1210/js.2017-00134.CrossRefPubMedPubMedCentral

89.

Omata K, Tomlins SA, Rainey WE. Aldosterone-producing cell clusters in normal and pathological states. Horm Metab Res. 2017;49(12):951–6. https://doi.org/10.1055/s-0043-122394.CrossRefPubMedPubMedCentral

90.

Williams TA, Gomez-Sanchez CE, Rainey WE, Giordano TJ, Lam AK, Marker A, et al. International Histopathology Consensus for Unilateral Primary Aldosteronism. J Clin Endocrinol Metab. 2021;106(1):42–54. https://doi.org/10.1210/clinem/dgaa484.CrossRefPubMed

91.

Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93(9):3266–81. https://doi.org/10.1210/jc.2008-0104.CrossRefPubMed

92.

Nishikawa T, Omura M, Satoh F, Shibata H, Takahashi K, Tamura N, et al. Guidelines for the diagnosis and treatment of primary aldosteronism--the Japan Endocrine Society 2009. Endocr J. 2011;58(9):711–21. https://doi.org/10.1507/endocrj.ej11-0133.CrossRefPubMed

93.

Vaidya A, Malchoff CD, Auchus RJ, Committee AAS. An individualized approach to the evaluation and management of primary aldosteronism. Endocr Pract. 2017;23(6):680–9. https://doi.org/10.4158/EP161717.RA.CrossRefPubMed

94.

Carey RM, Calhoun DA, Bakris GL, Brook RD, Daugherty SL, Dennison-Himmelfarb CR, et al. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association. Hypertension. 2018;72(5):e53–90. https://doi.org/10.1161/HYP.0000000000000084.CrossRefPubMed

95.

Rabi DM, McBrien KA, Sapir-Pichhadze R, Nakhla M, Ahmed SB, Dumanski SM, et al. Hypertension Canada’s 2020 comprehensive guidelines for the prevention, diagnosis, risk assessment, and treatment of hypertension in adults and children. Can J Cardiol. 2020;36(5):596–624. https://doi.org/10.1016/j.cjca.2020.02.086.CrossRefPubMed

96.

Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020;75(6):1334–57. https://doi.org/10.1161/HYPERTENSIONAHA.120.15026.CrossRefPubMed

97.

Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: Executive Summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71(19):2199–269. https://doi.org/10.1016/j.jacc.2017.11.005.CrossRefPubMed

98.

Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309–21. https://doi.org/10.1056/NEJMoa030207.CrossRefPubMed

99.

Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709–17. https://doi.org/10.1056/NEJM199909023411001.CrossRefPubMed

100.

Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386(10008):2059–68. https://doi.org/10.1016/S0140-6736(15)00257-3.CrossRefPubMedPubMedCentral

Titel: Primary Aldosteronism: a Continuum from Normotension to Hypertension
verfasst von: Taweesak Wannachalee
Adina F. Turcu
Publikationsdatum: 01.08.2021
Verlag: Springer US
Erschienen in: Current Cardiology Reports / Ausgabe 8/2021
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI: https://doi.org/10.1007/s11886-021-01538-8

Neu im Fachgebiet Kardiologie

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

VHF-Ablation nützt wohl nur bei reduzierter Auswurfleistung

02.05.2024 Ablationstherapie Nachrichten

Ob die Katheterablation von Vorhofflimmern bei Patienten mit Herzinsuffizienz die Komplikationsraten senkt, scheint davon abzuhängen, ob die Auswurfleistung erhalten ist oder nicht. Das legen die Ergebnisse einer Metaanalyse nahe.

Weniger Extremitätenischämien mit dualer Plättchenhemmung

02.05.2024 Thrombozytenaggregationshemmer Nachrichten

Eine Behandlung mit Ticagrelor zusätzlich zu ASS kann das Risiko für Revaskularisierungen und Amputationen von Extremitäten bei Diabetikern mit stabiler KHK deutlich reduzieren, vor allem für solche mit PAVK. Dafür spricht eine Auswertung der Interventionsstudie THEMIS.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Primary Aldosteronism: a Continuum from Normotension to Hypertension

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet Kardiologie

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

VHF-Ablation nützt wohl nur bei reduzierter Auswurfleistung

Weniger Extremitätenischämien mit dualer Plättchenhemmung

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

Update Kardiologie

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2021

Molecular Imaging Using Cardiac PET/CT: Opportunities to Harmonize Diagnosis and Therapy

Monogenic and Polygenic Models of Coronary Artery Disease

A Fishy Topic: VITAL, REDUCE-IT, STRENGTH, and Beyond: Putting Omega-3 Fatty Acids into Practice in 2021

Pulse-Cancellation Echocardiography for Clinical Evaluation of Myocardial Scar Burden

Anomalous Coronary Arteries: When to Follow-up, Risk Stratify, and Plan Intervention

Shared Care to Destination Therapy Left Ventricular Assist Device Site: a Novel Strategy to Start a Successful Mechanical Circulatory Support Program

Neu im Fachgebiet Kardiologie

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

VHF-Ablation nützt wohl nur bei reduzierter Auswurfleistung

Weniger Extremitätenischämien mit dualer Plättchenhemmung

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

Update Kardiologie